- Tools for Investors
- Stock News
- Investing Ideas
- Econ & Policy
- Personal Finance
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 1.93%.
ZIOPHARM Oncology, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share decreased to $-0.48 in the quarter versus EPS of $-0.19 in the year-earlier quarter.
Revenue: Was the same at $200,000 as the year-earlier quarter.
Actual vs. Wall St. Expectations: ZIOPHARM Oncology, Inc. reported adjusted EPS loss of $0.48 per share. By that measure, the company missed the mean analyst estimate of $-0.29. It beat the average revenue estimate of $0.
Quoting Management: There was no comment from management.
Key Stats (on next page)…
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
There's always a bull market in some sector! Find the best opportunities in commodities.